Theriva Biologics, Inc. (TOVX) Balance Sheet
TOVX balance sheet, 2025
December 31, 2025 · U.S. dollars$38.2M assets = $22.9M liabilities + $15.4M equity
Both columns are drawn to the same scale: what TOVX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TOVX financial health
Descriptive bands, not a rating. Fiscal 2025.
TOVX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $22.5M2016 | $38.2M2025 | +6.1%/yr | |
| Total liabilities | $20.2M2016 | $22.9M2025 | +1.4%/yr | |
| Shareholders’ equity | $3.8M2016 | $15.4M2025 | +16.7%/yr | |
| Cash & short-term investments | $19.1M2016 | $13.1M2025 | −4.1%/yr | |
| Total debt | $722,0002019 | $2.6M2025 | +24.0%/yr | |
| Net cash (debt) | $14.3M2019 | $10.4M2025 | −$3.9M | |
| Working capital | $1.8M2016 | $7.5M2025 | +$5.6M | |
| Book value per share | $5.372021 | $1.272025 | −30.3%/yr | |
| Current ratio | 1.092016 | 1.742025 | +0.65 | |
| Debt / equity | 0.052019 | 0.172025 | +0.12 | |
| Shares outstanding | 12.2M2021 | 12.1M2025 | −0.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TOVX assets
TOVX liabilities and equity
TOVX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TOVX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $13.1M | $11.6M | $23.2M | $41.8M | $67.3M | $6.2M | $15.0M | $28.9M | $17.1M | $19.1M |
| Cash & equivalents | $13.1M | $11.6M | $23.2M | $41.8M | $67.3M | $6.2M | $15.0M | $28.9M | $17.1M | $19.1M |
| Receivables | $3.8M | $3.3M | $1.9M | $231,000 | $0 | $469,000 | $3,000 | $0 | $46,000 | $185,000 |
| Inventory | $0 | $0 | $0 | −$231,000 | $0 | $0 | $1 | $0 | $0 | $0 |
| Other current assets | $576,000 | $1.3M | $2.3M | $3.7M | $1.5M | $1.2M | $1.4M | $593,000 | $781,000 | $2.3M |
| Total current assets | $17.5M | $16.3M | $27.4M | $45.5M | $68.9M | $7.9M | $16.4M | $29.5M | $17.9M | $21.6M |
| Property, plant & equipment (net) | $1.0M | $1.5M | $2.2M | $1.5M | $1.5M | $453,000 | $786,000 | $607,000 | $872,000 | $905,000 |
| Goodwill & intangible assets | $19.6M | $17.4M | $25.5M | $24.7M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $128,000 | $171,000 | $180,000 | $122,000 | $23,000 | $23,000 | $23,000 | $23,000 | $23,000 | $23,000 |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $70.4M | $8.4M | $17.2M | $30.1M | $18.8M | $22.5M |
| Liabilities | ||||||||||
| Accounts payable | $1.0M | $859,000 | $770,000 | $915,000 | $524,000 | $886,000 | $2.3M | $1.0M | $2.0M | $2.0M |
| Short-term debt | $606,000 | $600,000 | $550,000 | $273,000 | $124,000 | $287,000 | $249,000 | — | — | — |
| Deferred revenue | — | — | $2.9M | — | — | — | — | — | — | — |
| Total current liabilities | $10.0M | $7.6M | $6.7M | $7.1M | $3.6M | $3.0M | $5.3M | $3.4M | $9.8M | $19.8M |
| Long-term debt | $1.7M | $92,000 | $162,000 | $221,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $901,000 | $1.4M | $1.9M | $1.4M | $1.5M | $473,000 | $722,000 | — | — | — |
| Other long-term liabilities | $11.2M | $8.6M | $8.6M | $10.0M | $1.4M | $186,000 | $473,000 | $302,000 | $12.5M | $492,000 |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $5.0M | $3.2M | $5.7M | $3.7M | $22.2M | $20.2M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $34,000 | $3,000 | $18,000 | $16,000 | $13,000 | $29,000 | $17,000 | $15,000 | $129,000 | $117,000 |
| Retained earnings (deficit) | −$358.7M | −$335.0M | −$309.3M | −$291.0M | −$271.3M | −$248.1M | −$235.5M | −$219.5M | −$194.2M | −$172.0M |
| Accumulated other comprehensive income | $755,000 | −$1.2M | $32,000 | −$679,000 | — | — | — | $0 | −$12.1M | — |
| Total shareholders' equity | $15.4M | $19.1M | $39.7M | $54.6M | $65.4M | $8.0M | $14.4M | $29.4M | −$1.5M | $3.8M |
| Key figures | ||||||||||
| Total debt | $2.6M | $1.6M | $2.2M | $1.7M | $1.5M | $473,000 | $722,000 | — | — | — |
| Net cash (debt) | $10.4M | $10.0M | $21.0M | $40.1M | $65.8M | $5.8M | $14.3M | — | — | — |
| Working capital | $7.5M | $8.7M | $20.7M | $38.5M | $65.3M | $5.0M | $11.2M | $26.1M | $8.2M | $1.8M |
| Tangible book value | −$4.2M | $1.7M | $14.2M | $29.9M | $65.4M | $8.0M | $14.4M | $29.4M | −$1.5M | $3.8M |
| Book value per share | $1.27 | — | — | — | $5.37 | — | — | — | — | — |
| Shares outstanding | 12.1M | — | — | — | 12.2M | — | — | — | — | — |
| Current ratio | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Quick ratio | 1.69 | 1.97 | 3.73 | 5.95 | 18.94 | 2.26 | 2.85 | 8.55 | 1.75 | 0.97 |
| Debt / equity | 0.17 | 0.08 | 0.05 | 0.03 | 0.02 | 0.06 | 0.05 | — | — | — |
| Equity / assets | 40.2% | 53.9% | 71.9% | 75.9% | 93.0% | 95.5% | 83.3% | 97.4% | −7.9% | 17.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $11.3M | $14.4M | $13.1M | $7.5M | $12.1M | $10.0M | $11.6M | $16.4M | $16.6M | $18.3M | $23.2M | $31.2M |
| Cash & equivalents | $11.3M | $14.4M | $13.1M | $7.5M | $12.1M | $10.0M | $11.6M | $16.4M | $16.6M | $18.3M | $23.2M | $31.2M |
| Receivables | $1.8M | $1.8M | $3.8M | $1.8M | $1.9M | $1.7M | $3.3M | $2.0M | $1.9M | $1.9M | $1.9M | $1.6M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$1.6M |
| Other current assets | $525,000 | $540,000 | $576,000 | $551,000 | $744,000 | $766,000 | $1.3M | $1.1M | $1.2M | $1.5M | $2.3M | $3.6M |
| Total current assets | $13.7M | $16.8M | $17.5M | $9.9M | $14.7M | $12.5M | $16.3M | $19.5M | $19.7M | $21.7M | $27.4M | $34.8M |
| Property, plant & equipment (net) | $2.0M | $2.1M | $1.0M | $1.2M | $1.3M | $1.4M | $1.5M | $1.7M | $1.9M | $2.0M | $2.2M | $2.2M |
| Goodwill & intangible assets | $19.1M | $19.2M | $19.6M | $19.6M | $19.6M | $18.1M | $17.4M | $18.7M | $20.6M | $24.9M | $25.5M | $24.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $124,000 | $126,000 | $128,000 | $128,000 | $128,000 | $177,000 | $171,000 | $182,000 | $176,000 | $176,000 | $180,000 | $173,000 |
| Total assets | $34.9M | $38.2M | $38.2M | $30.8M | $35.8M | $32.2M | $35.4M | $40.1M | $42.4M | $48.7M | $55.2M | $61.5M |
| Liabilities | ||||||||||||
| Accounts payable | $984,000 | $608,000 | $1.0M | $795,000 | $607,000 | $437,000 | $859,000 | $756,000 | $935,000 | $571,000 | $770,000 | $833,000 |
| Short-term debt | $559,000 | $545,000 | $606,000 | $675,000 | $668,000 | $619,000 | $600,000 | $606,000 | $575,000 | $560,000 | $550,000 | $526,000 |
| Deferred revenue | — | — | — | — | — | — | — | — | $3.5M | — | — | — |
| Total current liabilities | $12.1M | $10.3M | $10.0M | $11.0M | $12.4M | $8.1M | $7.6M | $7.3M | $6.8M | $6.0M | $6.7M | $8.7M |
| Long-term debt | $1.6M | $1.6M | $1.7M | $1.7M | $1.6M | $1.5M | $92,000 | $98,000 | $93,000 | $159,000 | $162,000 | $150,000 |
| Lease obligations | $1.9M | $2.0M | $901,000 | $1.1M | $1.2M | $1.3M | $1.4M | $1.6M | $1.7M | $1.8M | $1.9M | $2.0M |
| Other long-term liabilities | $8.9M | $11.0M | $11.2M | $11.4M | $11.2M | $7.0M | $8.6M | $8.1M | $7.8M | $8.4M | $8.6M | $8.8M |
| Total liabilities | $22.7M | $22.8M | $22.9M | $24.1M | $25.2M | $16.7M | $16.3M | $15.5M | $14.7M | $14.6M | $15.5M | $17.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $45,000 | $45,000 | $34,000 | $9,000 | $8,000 | $3,000 | $3,000 | $3,000 | $23,000 | $18,000 | $18,000 | $18,000 |
| Retained earnings (deficit) | −$364.0M | −$360.8M | −$358.7M | −$356.7M | −$352.4M | −$339.3M | −$335.0M | −$330.5M | −$322.8M | −$314.5M | −$309.3M | −$303.8M |
| Accumulated other comprehensive income | $247,000 | $377,000 | $755,000 | $763,000 | $793,000 | −$524,000 | −$1.2M | $112,000 | −$709,000 | −$537,000 | $32,000 | −$1.1M |
| Total shareholders' equity | $12.2M | $15.4M | $15.4M | $6.7M | $10.6M | $15.5M | $19.1M | $24.6M | $27.6M | $34.1M | $39.7M | $43.9M |
| Key figures | ||||||||||||
| Total debt | $3.6M | $3.7M | $2.6M | $2.8M | $2.9M | $2.9M | $1.6M | $1.7M | $1.8M | $2.0M | $2.2M | $2.2M |
| Net cash (debt) | $7.8M | $10.7M | $10.4M | $4.8M | $9.2M | $7.2M | $10.0M | $14.7M | $14.8M | $16.2M | $21.0M | $28.9M |
| Working capital | $1.6M | $6.5M | $7.5M | −$1.1M | $2.3M | $4.3M | $8.7M | $12.2M | $12.9M | $15.6M | $20.7M | $26.0M |
| Tangible book value | −$6.9M | −$3.8M | −$4.2M | −$12.9M | −$9.0M | −$2.6M | $1.7M | $6.0M | $7.0M | $9.2M | $14.2M | $19.5M |
| Book value per share | $0.27 | $0.37 | $1.27 | $0.70 | — | — | — | — | — | — | — | — |
| Shares outstanding | 45.9M | 41.1M | 12.1M | 9.7M | — | — | — | — | — | — | — | — |
| Current ratio | 1.13 | 1.63 | 1.74 | 0.90 | 1.19 | 1.53 | 2.15 | 2.67 | 2.88 | 3.60 | 4.07 | 3.98 |
| Quick ratio | 1.09 | 1.58 | 1.69 | 0.85 | 1.13 | 1.44 | 1.97 | 2.51 | 2.70 | 3.36 | 3.73 | 3.74 |
| Debt / equity | 0.29 | 0.24 | 0.17 | 0.41 | 0.27 | 0.18 | 0.08 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 |
| Equity / assets | 35.0% | 40.3% | 40.2% | 21.9% | 29.6% | 48.2% | 53.9% | 61.4% | 65.2% | 70.0% | 71.9% | 71.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 12, 2026); data from EODHD.
TOVX financial position
At the end of fiscal 2025 (December 31, 2025), Theriva Biologics had total assets of $38.2 million (up 8.2% from a year earlier), total liabilities of $22.9 million and shareholders' equity of $15.4 million. It held $13.1 million in cash and short-term investments against $2.6 million of debt, a net cash position of $10.4 million. Its current ratio was 1.74. In the latest quarter (ended June 30, 2026) total assets were $34.9 million and equity $12.2 million.
Related: TOVX income statement, TOVX cash flow statement, TOVX key metrics. See the TOVX stock overview for the latest quote and news.
TOVX balance sheet FAQ
What are Theriva Biologics's total assets?
Theriva Biologics reported total assets of $38.2 million at the end of fiscal 2025 (December 31, 2025), compared with $35.4 million a year earlier.
How much debt does Theriva Biologics have?
Theriva Biologics had $2.6 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.17.
How much cash does Theriva Biologics have?
Theriva Biologics held $13.1 million in cash and short-term investments at the end of fiscal 2025; with $2.6 million of debt that is net cash of $10.4 million.
What is Theriva Biologics's book value?
Theriva Biologics's shareholders' equity (book value) was $15.4 million at the end of fiscal 2025, or $1.27 per share.
What is Theriva Biologics's current ratio?
Theriva Biologics had current assets of $17.5 million and current liabilities of $10.0 million, a current ratio of 1.74 (it can cover its short-term obligations).
How much goodwill does Theriva Biologics have?
Theriva Biologics carried $19.6 million of goodwill and intangible assets, 51.3% of total assets, at the end of fiscal 2025.